As stroke systems of care evolve, clinicians are increasingly torn between the known safety of traditional, aggressive ...

In this episode titled, Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

In combined analysis (n = 39), the average wound closure rate was 98%, and all 19 patients previously diagnosed for potential ...

A population-based study from Sweden upends conventional thinking on when patients with mantle cell lymphoma (MCL) can exhale ...

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

The approval of oral GLP-1 therapies marks a notable evolution in obesity management, expanding therapeutic choice beyond injectable options. Although this development could improve uptake among ...

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

New study findings are highlighting alopecia as a condition that reshapes identity, social relationships, and emotional wellbeing, leading researchers to argue for personalized, non-pharmacological ...

Retrospective ONCare Alliance Network data showed lower odds of new or worsened hypertension with acalabrutinib versus ibrutinib (OR 0.27; 95% CI, 0.074–0.98). Despite older age and higher baseline ...

1. Park K-W, Choi B, Moon D-H, Park S-M, Ye Y-M. Serum haptoglobin as a predictor of treatment response in patients with chronic spontaneous urticaria. Clin Trans Allergy. Published online January 7, ...